Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia

Table 1

Baseline univariate risk factors of survival and improvement in TCZ patients

	Survived (n = 116)	Deceased (n = 9)	value	Improved (n = 109)	Not Improved (n = 16)	value
Age (years)	47.25 ± 12.52	60.89 ± 10.54	0.002	46.59 ± 12.33	59.44 ± 10.83	<0.001
Sex: Male	93	5	0.1	88	10	0.111
PaO2 (mmHg)	74.60 ± 30.68	84.11 ± 25.77	0.373	75.91 ± 31.54	73.50 ± 23.62	0.773
SpO2 (%)	90.56 ± 7.06	90.22 ± 4.99	0.888	90.83 ± 7.06	88.56 ± 5.64	0.223
Days from onset to hospitalization	7.47 ± 2.95	7.67 ± 3.24	0.845	7.48 ± 2.96	7.50 ± 2.98	0.977
Days from onset to TCZ	9.19 ± 3.17	11.56 ± 3.90	0.036	9.29 ± 3.17	9.81 ± 3.97	0.556
CRP (mg/dl)	115.7 ± 69.34	63.40 ± 40.91	0.028	112.9 ± 68	105 ± 76.98	0.671
LDH (U/L)	364.1 ± 156.9	544.3 ± 142.5	0.054	361 ± 146.5	447.8 ± 233.6	0.125
D-dimer (ng/ml)	545.5 ± 819.1	1445 ± 1808	0.176	537.2 ± 839	1144 ± 1429	0.129
Ferritin (ng/ml)	605.6 ± 512.4	1600 ± 2322	0.235	604.1 ± 525.6	1175 ± 1775	0.22
ALT (U/L)	56.16 ± 47.80	57.22 ± 34.89	0.948	54.09 ± 46.74	70.81 ± 46.68	0.184
ANC (10^3/µl)	8617 ± 4668	9223 ± 2287	0.017	8477 ± 4497	9223 ± 4681	0.047
NLR	12.49 ± 10.68	21.54 ± 13.50	0.018	12.28 ± 10.58	19.01 ± 13.01	0.023
S.Cr (mg/dl)	0.9 ± 0.22	1 ± 0.41	0.539	0.9 ± 0.2	1.02 ± 0.39	0.237
Procalcitonin (ng/ml)	0.314 ± 0.876	0.33 ± 0.417	0.956	0.303 ± 0.894	0.398 ± 0.432	0.686
CT involvement (%)	54.59 ± 14.37	49.38 ± 21.98	0.343	53.64 ± 14.07	58.57 ± 20.32	0.248
NIV Status	63	3	0.305	57	9	0.796
Intubation Status	3	2	0.041	3	2	0.122
Vaccination Status	13	1	1.00	12	2	1.00

ALT: Alanine transaminase, ANC: Absolute Neutrophil Count, CRP: C-Reactive Protein, LDH: Lactate Dehydrogenase, NIV: Noninvasive Ventilation, NLR: Neutrophil-Lymphocyte Ratio, S.Cr: Serum Creatinine